37 results about "Human herpesvirus" patented technology

Aspects of the present invention use gene expression profiling, and gene silencing methods to identify and provide a plurality of ‘validated’ KSHV-induced cellular gene sequences and pathways useful as targets for modulation of KSHV-mediated effects on cellular proliferation and phenotype (e.g., cancer) associated with latent and lytic phases of the Kaposi's sarcoma-associated herpesvirus (KSHV; Human herpesvirus 8; HHV8) life cycle. Particular embodiments provide therapeutic compositions, and methods for modulation and treatment of KSHV infection or KSHV-mediated effects on cellular proliferation and phenotype, comprising inhibition of KSHV-induced gene sequences or products thereof. Additional embodiments provide screening assays for compounds useful to modulate KSHV infection or KSHV-mediated effects on cellular proliferation and phenotype. Further embodiments provide diagnostic and / or prognostic assays for KSHV infection or related conditions. Additional embodiments provide novel in vivo models for KSHV infection or related conditions. Yet further aspects provide novel methods for transforming a mammalian cell, comprising expressing, by recombinant means, a transforming amount of RDCI, Neuritin, or both, and further provide cells transformed thereby.

Level of fatigue that accompanies everyday life or a disease can be simply, easily, and quantitatively assessed by obtaining a body fluid from a test subject and measuring the amount of human herpesvirus in the body fluid. Furthermore, the anti-fatigue potency of anti-fatigue substances and anti-fatigue food products can be measured.

The invention discloses application of spironolactone in preparation of a drug for treating human herpesvirus infection. We evaluate the effect of resisting Kaposi's sarcoma-associated herpes virus KSHV and herpes simplex viruses HSV-1 and HSV-2 of the spironolactone by measuring the level of infectious virion production, the level of DNA replication during lysis, or the degree of cytopathic effect caused by the virus. The spironolactone has significant antiviral activity and a dose-dependent effect, can inhibit the activation of replication during KSHV lysis with a half inhibitory concentration (IC50) of 1.145 microM to KSHV infectious virions. At non-toxic concentration, the spironolactone is effective in reducing cytopathic effect caused by HSV-1 and HSV-2. The spironolactone is a complete inhibitor of mineralocorticoids (such as aldosterone). The spironolactone is clinically used for inhibiting sodium reabsorption, potassium excretion, diuresis and the like of organisms and has thesmall toxic and side effects on the human body. The compound can inhibit replication of herpes virus in the lysis phase, and has a wide prospect of being developed into the drug for treating human herpes virus infection.

The invention provides a real-time fluorescent quantitation PCR (polymerase chain reaction) parting detection kit for human herpesvirus-6 (HHV-6). The real-time fluorescent quantitation PCR parting detection kit consists of quantitation PCR reaction liquid, an HHV-6A standard substance, an HHV-6B standard substance, an HHV-6A positive reference substance, an HHV-6B positive reference substance, a negative reference substance, a specification and a kit body, wherein the quantitation PCR reaction liquid contains a PCR buffer solution, MgCl2, dNTPs, heat-resistant DNA polymerase, an upstream amplification primer, a downstream amplification primer, an HHV-6A fluorescent probe and an HHV-6B fluorescent probe. By the adoption of a real-time fluorescent quantitation PCR technology and a double-color fluorescent probe, the kit disclosed by the invention can detect two subtypes of the HHV-6 by a one-step method; the HHV-6A and HHV-6B in the sample can be simultaneously parted; a positive virus subtype can be accurately quantified in real time; the urgent need of early and acute parting diagnosis on the HHV-6 infection can be met; a basis is supplied to epidemiological investigation and targeted treatment on the HHV-6 infection.

The present disclosure provides various cyanobacterial extracts exhibiting antiviral activity to a wide spectrum of viruses, such as enterovirus (EV), respiratory syncytial virus (RSV), Human Herpesvirus (HHV), Ebola virus, porcine epidemic diarrhea virus (PEDV), and porcine reproductive and respiratory syndrome virus (PRRSV). The cyanobacterial extract is prepared from biomass of A. maxima (or Spirulina maxima). Also disclosed herein are process for preparing the cyanobacterial extract and uses of the cyanobacterial extract.

The invention discloses a method for producing immune cells and a method for inducing immune effector cells. The method for producing the immune cells comprises the following step: carrying out mixed culture on the immune cells and an immunogen composition, wherein, the immunogen composition comprises at least two types of peptide derived from human herpesvirus-4 or a peptide library and can alsocomprise an immuno-adjuvant. In addition, the method for inducing the immune effector cells: mixing antigen presenting cells with the immunogen composition to obtain a culture; and co-culturing the obtained culture with lymphocyte in an appropriate culture medium to obtain activated immune effector cells, wherein, the culture medium can also comprise the immuno-adjuvant, and the obtained activated immune effector cell can be used for producing anti-EBA (Epstein-Barrvirus) immune reaction.

The invention provides compositions, methods, and kits for the diagnosis or detection of active, latent, or prior infection with human herpesvirus 8 in a subject sample.

The invention relates to a gene chip capable of simultaneously detecting human herpes virus and enterovirus. The gene chip comprises a nucleotide extraction kit, a simultaneous DNA (Deoxyribonucleic Acid) and RNA (Ribonucleic Acid) reverse transcription kit, a simultaneous DNA and RNA PCR amplification kit and a gene chip linked with a specific probe. According to the invention, the simultaneous extraction, amplification and detection of nucleic acid of a plurality of herpes viruses and intestinal viruses can be realized by only 100 mu l of cerebrospinal fluid. The gene chip has the advantages of less required sample amount, fast extraction speed, high amplification efficiency, reliable results and strong specificity. The early diagnosis and treatment of clinical viral encephalitis and meningitis induced by the viruses can be achieved and the current bottleneck problem of the detection of viruses in clinical cerebrospinal fluid is resolved.

The invention discloses a real-time fluorescence nucleic acid isothermal amplification detection kit for human herpesvirus 1 (HSV-1). The real-time fluorescence nucleic acid isothermal amplification detection kit specifically comprises a capturing probe, a T7 primer and an nT7 primer of HSV-1, an HSV-1 detection probe, M-MLV reverse transcriptase, T7RNA polymerase, and other reagent. The method provided by the invention can perform nucleic acid isothermal amplification detection on swab, scraping liquid and cerebrospinal liquid samples containing the HSV-1 in a high specificity, high sensitivity, low pollution and rapid manner; and the kit has the characteristics of high detection efficiency and high accuracy, so that the kit has bright application prospects.

The invention relates to the technical field of medicines, in particular to application of pingbeinone in preparation of drugs for preventing and / treating human herpes viral infection. It is found through research that the pingbeinone can inhibit reproduction of human herpes viruses, relieve the symptoms caused by the human herpes viruses, decreased death caused by the human herpes viral infection, improve the survival rate of rats and average survival rate and prolong the life and shows dose-dependent relation. It is shown that the pingbeinone can effectively prevent and treat the diseases caused by the human herpes viral infection.

The present invention relates to primer compositions and methods for identifying and distinguishing CMV, EBV-A / B, HSV-1 / 2, HHV-6 and VZV herpesviruses in a sample.